Share on StockTwits

CorMedix (NASDAQ:CRMD) CEO Randy Milby acquired 3,125 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 29th. The shares were purchased at an average cost of $2.00 per share, with a total value of $6,250.00. Following the acquisition, the chief executive officer now directly owns 15,247 shares in the company, valued at approximately $30,494. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

CorMedix (NASDAQ:CRMD) traded down 5.00% during mid-day trading on Tuesday, hitting $1.90. The stock had a trading volume of 100,583 shares. CorMedix has a 52-week low of $0.66 and a 52-week high of $3.20. The stock has a 50-day moving average of $1.95 and a 200-day moving average of $1.97. The company’s market cap is $41.5 million.

CorMedix (NASDAQ:CRMD) last posted its quarterly earnings results on Wednesday, August 20th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.13. Analysts expect that CorMedix will post $-0.61 EPS for the current fiscal year.

A number of research firms have recently commented on CRMD. Analysts at Zacks downgraded shares of CorMedix to a “neutral” rating in a research note on Monday, July 28th. They now have a $2.20 price target on the stock. Analysts at Roth Capital initiated coverage on shares of CorMedix in a research note on Thursday, July 24th. They set a “buy” rating and a $3.00 price target on the stock.

CorMedix Inc (NASDAQ:CRMD) is a biopharmaceutical company that focuses on in-licensing, developing and commercializing therapeutic products for the treatment of cardiac and renal dysfunction, also know as Cardiorenal disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.